Evidence map›Paper›PMID 40938733›Full record

ArticleBlood advances2026

Developing an artificial intelligence-generated peptide targeting platelet-type von Willebrand disease.

Thomas D D Kazmirchuk, Jiashu Wang, Loredana Bury, Emanuela Falcinelli, Calvin Bradbury-Jost, Anastasiia Koziar, Mustafa Al-Gafari, Sarah Takallou, William G Willmore, Frank Dehne and 3 more

Abstract read
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Thomas D D KazmirchukDepartment of Biology, Ottawa Institute of Systems Biology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.ORCID 0000-0003-2962-6819
Jiashu WangDepartment of Biology, Ottawa Institute of Systems Biology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.ORCID 0009-0007-6264-8864
Loredana BurySection of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.ORCID 0000-0003-0333-0948
Emanuela FalcinelliSection of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.ORCID 0000-0001-6078-3041
Calvin Bradbury-JostDepartment of Biology, Ottawa Institute of Systems Biology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.ORCID 0009-0009-9594-1164
Anastasiia KoziarDepartment of Biology, Ottawa Institute of Systems Biology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Mustafa Al-GafariDepartment of Biology, Ottawa Institute of Systems Biology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.ORCID 0000-0002-3877-6707
Sarah TakallouDepartment of Biology, Ottawa Institute of Systems Biology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
William G WillmoreDepartment of Biology, Faculty of Science, Carleton University, Ottawa, ON, Canada.ORCID 0000-0003-3874-7954
Frank DehneSchool of Computer Science, Faculty of Science, Carleton University, Ottawa, ON, Canada.
Paolo GreseleSection of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Maha OthmanDepartment of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, ON, Canada.
Ashkan GolshaniDepartment of Biology, Ottawa Institute of Systems Biology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.ORCID 0009-0008-9171-6245

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractPlatelet-type von Willebrand disease (PT-VWD) refers to a rare bleeding disorder caused by gain-of-function mutations in platelet glycoprotein Ibα (GPIbα). These mutations lead to a hyperactive protein-protein interaction (PPI) with von Willebrand factor (VWF) and pathological platelet aggregation. Counterintuitively, patients with PT-VWD present with a bleeding diathesis as opposed to thrombosis. Despite well-defined genetic etiology, no targeted therapy exists for PT-VWD. Here, we sought to develop a peptide inhibitor that selectively targets the aberrant interaction in PT-VWD. Using the In Silico Protein Synthesizer, we designed and screened 10 000 peptides for predicted affinity and specificity toward GPIbαMet239Val. Functional validation of top-ranked peptides included a combination of in vitro functional assays using GPIbαGly233Val, Met239Val and ex vivo platelet assays from patients with PT-VWD. One peptide, G14, emerged as a potent and selective inhibitor of the GPIbαGly233Val, Met239Val-VWF PPI. Functional assays demonstrated that G14 disrupts this interaction without binding GPIbαWT or VWF alone. The peptide also displays picomolar affinity (6.6 pM) for GPIbαGly233Val, Met239Val. Structural modeling predicted G14 binds the β-switch region of GPIbαGly233Val, Met239Val involving the disease-associated Val239 residue. In platelet-rich plasma from a patient with PT-VWD, G14 selectively inhibited platelet-VWF binding and ristocetin-induced agglutination, with no measurable effect on healthy samples. The G14 peptide appears to be a highly specific inhibitor of the GPIbαGly233Val, Met239Val-VWF interaction, providing proof-of-concept data for therapeutic development in PT-VWD. Furthermore, the protein and platelet specificity of these data suggest that G14 may be a potential diagnostic tool for PT-VWD. The approach highlights the utility of artificial intelligence in targeting disease-specific PPIs with high precision.

Indexed as

Blood PlateletsPeptidesvon Willebrand DiseasesHumansPlatelet AggregationPlatelet Glycoprotein GPIb-IX ComplexProtein Bindingvon Willebrand FactorPeptidesPlatelet Glycoprotein GPIb-IX Complexvon Willebrand Factor

Identifiers

PMID40938733
PMCPMC12848357

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.